Skip to main content

Table 2 Frequency of immunostaining and KRAS mutations among breast cancer tumors.

From: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

Subtype

Samples

CK5/6+ (%)

EGFR+ (%)

CK/EGFR+ (%)*

KRASmut (%)

TN

35

17 (48.6)

25 (71.4)

15 (42.8)

0 (0.0)

BS

27

17 (63.0)

25 (92.6)

15 (55.5)

0 (0.0)

  1. *Positive staining for both CK5/6 and EGFR
  2. Abbreviations: TN, triple-negative; BS, basal-like; CK, cytokeratin 5/6; KRAS mut, mutant KRAS